|drug447||Biological sample collection Wiki||0.71|
|drug1676||Interferon beta-1b Wiki||0.58|
There is one clinical trial.
To conduct an open-label randomized controlled trial on a short course of interferon β-1b and clofazimine combination treatment for patients hospitalized for COVID-19 infection. To assess its safety and clinical efficacy.
Description: Time to complete alleviation of symptoms as defined by NEWS of 0 maintained for 24 hoursMeasure: Clinical alleviation of symptoms Time: 7 days
Description: Length of hospitalisationMeasure: Hospitalisation Time: 14 days
Description: Time to negative nasopharyngeal swab, throat saliva and sputum viral load by RT-PCRMeasure: Time to negative viral load Time: 7 days
Description: Cytokine/ chemokine changesMeasure: Inflammatory changes Time: 7 days
Description: One month mortality rateMeasure: Mortality Time: 30 days
Description: Adverse events during and shortly after treatmentMeasure: Adverse events Time: 30 days
Data processed on January 01, 2021.